Advertisment

Interbrand study ranks Pfizer, the Roche Group and Merck & Co as the top three biopharma brands

The study rates biopharma companies on their ability to address the needs of health care professionals, payers and policy-makers

author-image
BestMediaInfo Bureau
New Update
Interbrand study ranks Pfizer, the Roche Group and Merck & Co as the top three biopharma brands

Interbrand study ranks Pfizer, the Roche Group and Merck & Co as the top three biopharma brands

The study rates biopharma companies on their ability to address the needs of health care professionals, payers and policy-makers

BestMediaInfo Bureau | Mumbai | April 1, 2016

interbrand

A global study released by Interbrand Health recently, identified biopharma companies that are addressing the needs of healthcare professionals, (HCPs), payers and policy-makers. A commitment to brand, the study noted, was a promise to address healthcare challenges and meet the needs of these healthcare professionals.

The study examined what value meant to HCPs and illustrated the influence the corporate brand had in conveying that value. It revealed how leading companies were beginning to deliver on what mattered to HCPs.

Interbrand is a leading brand consultancy, with a network of 31 offices in 27 countries. The study on 'Best Pharma Brands' is Interbrand Health's inaugural top ten ranking that quantifies the corporate brand's contribution to business performance in the biopharma industry. In the ranking, multinationals Pfizer, the Roche Group and Merck & Company qualified as the best three biopharma brands in the world.

Best Pharma Brands ranks these leading companies by qualifying the industry's definition of value through brand, then quantifying the corporate brand's contribution to business performance. The ranking identifies the ten most valuable biopharma brands. In total, these ten brands represent approximately US $129 billion in brand value. Pfizer and the Roche Group secure the #1 and #2 positions in the ranking.

Best Pharma Brands also sets an important industry benchmark by highlighting the need for biopharma companies to change how they interact with the market and meet the needs of the healthcare community.

Looking to the future, healthcare professionals desire a commitment to innovative healthcare solutions that go 'beyond the pill'. As a result, leading biopharma companies are adapting their business models, increasing transparency, exploring non-traditional solutions in areas like digital therapies and ramping up their corporate citizenship activities. “Biopharma is at a pivotal moment, and the time for change is now,” said Jane Parker, Interbrand Health's CEO.

Ronnie Hershman, a cardiologist affiliated with NYU Langone Long Island Cardiac Care and the CEO of HealthEffect, LLC, said, “The biopharma industry has relied on blockbuster drugs for a long time, but healthcare is changing, and what physicians need has changed. Biopharma companies need to shift and think about what else they can offer.”

Ashish Mishra Ashish Mishra

Commenting on the Best Pharma Brands report, Ashish Mishra, Managing Director of Interbrand India, said, “Best Pharma Brands is an important league table to study in the Indian market. Whether it is our annual Best Global Brands league table or the Best Pharma Brands being shared here, we do not have any Indian brand featuring yet. This is the absence that we would like to address. The key insight from the Best Pharma Brands is to lay stronger emphasis on the master brand and this can surely be leveraged to create clearer strategic pathways for growing Indian pharma brands.”

Parker pointed out that the ten biopharma brands in question were “embracing a strategy that is somewhat new to the health and life sciences sector”. She said, “They are effectively leveraging their corporate brands and, in doing so, they are growing their businesses, fueling innovation, and developing meaningful solutions for patients on a global scale.”

Best Pharma Brands is powered by global research data, feedback from HCPs, and data-driven insights. The underlying methodology mirrors Interbrand's Best Global Brands, which demonstrates that strong brands can withstand market volatility and are more likely to outperform key financial indices, like the S&P 500.

To be considered, biopharma brands must have a global presence, generate revenue from the sale of prescription medicines, report the ratio of revenues generated from sales of prescription medicines, possess a strong pipeline of potential future prescription medicines, have awareness among HCPs and serve as the primary external-facing manufacturer brand.

The report may be downloaded at BestPharmaBrands.com. To join the conversation on social media, use the hashtag #BestPharmaBrands.

Best Pharma Brands Ranking

#1 Pfizer (US $19.985 billion)

#2 Roche Group (US $15.479 billion)

#3 Merck & Co., Inc., Kenilworth, N.J., U.S.A. (US $13.880 billion)

#4 Janssen: The Janssen Pharmaceutical Companies of Johnson & Johnson (US $13.866 billion)

#5 Novartis (US $13.496 billion)

#6 Amgen (US $13.461 billion)

#7 Gilead Sciences (US $13.361 billion)

#8 Novo Nordisk (US $10.206 billion)

#9 AstraZeneca (US $8.123 billion)

#10 GSK (US $6.778 billion)

Best-Pharma-Brands

Info@BestMediaInfo.com

Info@BestMediaInfo.com

Advertisment